Event Details
ASCO 2021
Jun 04 2021
Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals.
The conference will take place from 4 to 8 June in virtual format.
The Meeting offers healthcare professionals providing oncology care an important opportunity to come together to explore the latest advances in science; contextualize recent discoveries and optimize treatment and research strategies; frame and critically evaluate major controversies in the field; and network with peers in an environment charged with the excitement of a common goal: progress toward better outcomes for patients.
Agenda
Priming Immune Response plus Immunotherapy Combination
Abstract #2590: A phase I trial evaluating NTXR3 activated by RT in combination with nivolumab or pembrolizumab in patients with advanced cancer by Colette Shen, MD, PhD
Local Control as a Single-Agent for Patients with Head and Neck Cancer
Abstract #6051: Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by RT in cisplatin-ineligible locally advanced HNSCC patients by Christophe Le Tourneau, MD, PhD
Local Control as a Single-Agent for Patients with Soft Tissue Sarcoma
Abstract #11544: Long term evaluation of the novel radioenhancer NBTXR3 + RT in patients with locally advanced STS treated in phase II/III Act.In. Sarc trial by Sylvie Bonvalot, MD, PhD
Tumor-Agnostic, Therapeutic Combination-Agnostic Development Potential
Abstract #2591: Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: from bench to bed side by Tanguy Seiwert, MD